JHS Sven.Lab.

Who are in the management team of JHS Sven.Lab.?

As of March 2021, the management team of JHS Sven.Lab includes Nikhil Nanda (Managing Director), Rajagopal Chakravarthi (Chairman & Independent Director), and several other independent and additional directors, along with a Company Secretary.

As of March 2021, the management team of JHS Sven.Lab. includes the following individuals:<BR><BR>1. Nikhil Nanda - Managing Director<BR>2. Mukul Pathak - Independent Director<BR>3. Rohina Sanjay Sangtani - Independent Director<BR>4. Rajagopal Chakravarthi - Chairman & Independent Director<BR>5. Kapil Minocha - Independent Director<BR>6. Sunil Arora - Additional Independent Director<BR>7. Vinay Mittal - Additional Director<BR>8. Komal - Company Secretary & Compliance Officer<BR>9. Upma Chawdhry - Additional Director<BR><BR>This team comprises a mix of directors and officers, with Nikhil Nanda serving as the Managing Director.

What does JHS Sven.Lab. do?

JHS Svendgaard Laboratories Ltd is a micro-cap company that manufactures a range of oral care products. As of March 2025, it reported net sales of 25 Cr and a net loss of 7 Cr, with a market cap of Rs 111 Cr.

Overview:<BR>JHS Svendgaard Laboratories Ltd manufactures a comprehensive range of oral care products and operates within the FMCG industry, classified as a micro-cap company.<BR><BR>History:<BR>The company was incorporated in an unspecified year and has maintained its status as a manufacturer of oral care products. The latest quarterly results reported are for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 25 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -7 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 111 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 54 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.08 <BR>Return on Equity: -9.78% <BR>Price to Book: 0.64<BR><BR>Contact Details:<BR>Address: Trilokpur Road Kheri(Kala Amb), Tehsil Nahan District Sirmour Himachal Pradesh : 173030 <BR>Tel: 91-9218-400346 <BR>Email: cs@svendgaard.com <BR>Website: http://www.svendgaard.com

Has JHS Sven.Lab. declared dividend?

Yes, JHS Svendgaard Laboratories Ltd has declared an 8% dividend, amounting to 0.80 per share, with an ex-date of December 26, 2011. However, the company has experienced significant declines in total returns over multiple periods, with the most recent five-year period showing only a slight positive return of 1.1%.

Yes, JHS Svendgaard Laboratories Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 8%<BR>- Amount per share: 0.80<BR>- Ex-date: 26 Dec 11<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -46.21%, the dividend return was 0%, resulting in a total return of -46.21%.<BR><BR>For the 1-year period, the price return was -36.81%, the dividend return was 0%, leading to a total return of -36.81%.<BR><BR>Over the 2-year period, the price return was -23.29%, the dividend return was 0%, which resulted in a total return of -23.29%.<BR><BR>In the 3-year period, the price return was -48.05%, the dividend return was 0%, culminating in a total return of -48.05%.<BR><BR>During the 4-year period, the price return was -40.37%, the dividend return was 0%, giving a total return of -40.37%.<BR><BR>For the 5-year period, the price return was 1.1%, the dividend return was 0%, resulting in a total return of 1.1%.<BR><BR>Overall, while JHS Svendgaard Laboratories Ltd declared a dividend in the past, the recent total returns indicate significant declines over multiple periods, with the most recent five-year period showing only a slight positive return. The lack of recent dividends suggests a challenging financial environment for the company.

Who are the peers of the JHS Sven.Lab.?

Peers of JHS Sven.Lab. include Hind. Unilever, ITC, Nestle India, Britannia Inds., Godrej Consumer, Ovobel Foods, Shri Vasuprada, Kovil. Lak. Rol., and Shivam, with JHS Sven.Lab. showing average management risk and a 1-year return of -35.83%.

Peers: The peers of JHS Sven.Lab. are Hind. Unilever, ITC, Nestle India, Britannia Inds., Godrej Consumer, Ovobel Foods, Shri Vasuprada, Kovil. Lak. Rol., and Shivam.<BR><BR>Quality Snapshot: Excellent management risk is observed at ITC, Nestle India, and Britannia Inds., while Good management risk is found at Hind. Unilever, Godrej Consumer, Ovobel Foods, and Shivam. Average management risk is present at JHS Sven.Lab. and Kovil. Lak. Rol., while Below Average management risk is noted at Shri Vasuprada. Growth is Average at Nestle India and Ovobel Foods, while Below Average growth is seen at Hind. Unilever, ITC, Britannia Inds., Godrej Consumer, JHS Sven.Lab., Shivam, Kovil. Lak. Rol., and Shri Vasuprada. Capital Structure is Excellent for Hind. Unilever, ITC, Nestle India, Britannia Inds., Godrej Consumer, and Ovobel Foods, while JHS Sven.Lab., Kovil. Lak. Rol., and Shri Vasuprada have Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Shri Vasuprada at 29.17%, while JHS Sven.Lab. has a 1-year return of -35.83%, which is significantly lower. Additionally, the six-month return is negative for JHS Sven.Lab., Godrej Consumer, and Kovil. Lak. Rol.

Is JHS Sven.Lab. overvalued or undervalued?

As of March 31, 2023, JHS Sven.Lab. is rated as risky and appears undervalued with a PE ratio of -6.59 and a year-to-date return of -37.5%, indicating significant financial distress compared to its peers like Hindustan Unilever and Nestle India.

As of 31 March 2023, the valuation grade for JHS Sven.Lab. moved from does not qualify to risky. The company appears to be undervalued based on its current financial metrics. Key ratios include a PE ratio of -6.59, an EV to EBITDA of -24.39, and a Price to Book Value of 0.64, indicating significant financial distress compared to its peers.<BR><BR>In comparison to its industry peers, JHS Sven.Lab. shows stark contrasts, particularly when compared to Hindustan Unilever with a PE ratio of 53.88 and Nestle India at 75.2, both categorized as very expensive. The company's recent stock performance has been challenging, with a year-to-date return of -37.5%, contrasting sharply with the Sensex's 6.20% gain during the same period. This suggests that while the stock may be undervalued, it faces significant operational challenges that investors should consider.

What is the technical trend for JHS Sven.Lab.?

As of May 30, 2025, JHS Sven.Lab. exhibits a bearish trend with moderate strength, supported by bearish indicators across multiple time frames, despite some mixed signals in momentum.

As of 30 May 2025, the technical trend for JHS Sven.Lab. has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. The weekly MACD is mildly bullish, but the monthly MACD is bearish, indicating a divergence in momentum. Both the weekly and monthly Bollinger Bands are bearish, reinforcing the downward pressure. Daily moving averages are also bearish, suggesting short-term weakness. The KST shows a mildly bullish signal on the weekly but is bearish on the monthly, while the Dow Theory indicates a mildly bearish trend on the weekly and mildly bullish on the monthly, reflecting mixed signals. Overall, the OBV is mildly bearish on both time frames, contributing to the bearish outlook.

Who are the top shareholders of the JHS Sven.Lab.?

The top shareholders of JHS Sven.Lab. include Nikhil Nanda with 30.95%, individual investors with 46.91%, and Vijay Mohan Govila as the highest public shareholder at 2.8%. Additionally, four foreign institutional investors hold a combined 1.6%, while mutual funds hold no shares.

The top shareholders of JHS Sven.Lab. include Nikhil Nanda, who is the promoter with the highest holding at 30.95%. Individual investors collectively hold 46.91% of the shares. Additionally, Vijay Mohan Govila is noted as the highest public shareholder with a stake of 2.8%. The company also has 4 foreign institutional investors (FIIs) holding a combined 1.6% of the shares, while mutual funds do not hold any shares in this company.

How big is JHS Sven.Lab.?

As of 24th July, JHS Svendgaard Laboratories Ltd has a market capitalization of 109.00 Cr, with net sales of 91.99 Cr and a net loss of 19.75 Cr over the latest four quarters. The balance sheet as of March 2024 shows shareholder's funds of 169.88 Cr and total assets of 186.53 Cr.

As of 24th July, JHS Svendgaard Laboratories Ltd has a market capitalization of 109.00 Cr, categorized as a Micro Cap.<BR><BR>In the latest four quarters, the company reported net sales of 91.99 Cr. However, it experienced a loss of 19.75 Cr in net profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2024, showing shareholder's funds of 169.88 Cr and total assets amounting to 186.53 Cr.

How has been the historical performance of JHS Sven.Lab.?

JHS Sven.Lab. has faced significant financial challenges, with fluctuating net sales and increasing losses, reporting a profit after tax of -19.74 Cr in March 2025 and negative cash flow from operating activities of -5.00 Cr. Total liabilities matched total assets at 197.87 Cr, indicating a difficult financial position.

Answer:<BR>The historical performance of JHS Sven.Lab. shows a fluctuating trend in net sales and profitability over the years, with significant losses in recent periods.<BR><BR>Breakdown:<BR>JHS Sven.Lab. reported net sales of 92.00 Cr in March 2025, an increase from 70.80 Cr in March 2024, but a decline from 96.21 Cr in March 2023. The total operating income mirrored this trend, reaching 92.00 Cr in March 2025, while total expenditure rose to 96.01 Cr, leading to an operating profit (PBDIT) of -1.13 Cr for the same period. This marked a deterioration from the previous year's operating profit of 3.38 Cr. The company faced a profit before tax of -12.51 Cr in March 2025, worsening from -3.43 Cr in March 2024, and a profit after tax of -19.74 Cr, compared to -4.06 Cr in the prior year. The earnings per share also reflected this decline, showing -2.31 in March 2025. On the balance sheet, total liabilities increased to 197.87 Cr in March 2025, while total assets were reported at 197.87 Cr, indicating a challenging financial position. Cash flow from operating activities was negative at -5.00 Cr, contributing to a net cash outflow of -2.00 Cr for the year. Overall, JHS Sven.Lab. has experienced significant financial challenges, particularly in profitability and cash flow, over the recent years.

Should I buy, sell or hold JHS Sven.Lab.?

When is the next results date for JHS Svendgaard Laboratories Ltd?

The next results date for JHS Svendgaard Laboratories Ltd is 10 February 2026.

The next results date for JHS Svendgaard Laboratories Ltd is scheduled for 10 February 2026.

Are JHS Svendgaard Laboratories Ltd latest results good or bad?

JHS Svendgaard Laboratories Ltd's latest results are concerning, showing a net loss of ₹0.20 crores in Q2 FY26, a decline from a profit in the previous quarter, despite a 13.21% year-on-year revenue growth. The company has faced ongoing unprofitability, with six net losses in the last seven quarters, indicating significant operational challenges.

The latest results for JHS Svendgaard Laboratories Ltd indicate a challenging situation for the company. In Q2 FY26, the company reported a net loss of ₹0.20 crores, which is a significant decline from the profit of ₹1.06 crores in the previous quarter. This marks a concerning trend, as it reflects a return to losses after a brief profitable quarter.<BR><BR>While the revenue for the quarter was ₹22.28 crores, showing a year-on-year growth of 13.21%, this growth did not translate into profitability. The operating margin also decreased sharply to 4.08%, down from 7.08% in Q1 FY26, indicating margin compression likely due to increased costs or operational inefficiencies.<BR><BR>Additionally, the company's profit after tax (PAT) margin turned negative at -0.90%, highlighting ongoing issues with profitability. Over the past seven quarters, JHS Svendgaard has reported net losses in six of them, raising concerns about the sustainability of its business model.<BR><BR>Overall, while there are some positive aspects, such as year-on-year revenue growth and a debt-free balance sheet, the persistent unprofitability and operational challenges suggest that the latest results are more negative than positive. The company faces significant hurdles in achieving consistent profitability and improving its financial performance.

Why is JHS Svendgaard Laboratories Ltd falling/rising?

As of 31-Mar, JHS Svendgaard Laboratories Ltd is facing a significant decline in stock price, currently at Rs. 6.32, with a year-to-date drop of -35.90% and a 52-week low of Rs. 6.15. The stock's persistent weakness is attributed to poor fundamentals, reduced investor participation, and consistent underperformance against market benchmarks.

As of 31-Mar, JHS Svendgaard Laboratories Ltd is experiencing a decline in its stock price, currently at Rs. 6.32, which reflects a change of -0.59 or -8.54%. The stock has underperformed significantly over various time frames, with a 1-week decline of -8.27% and a staggering 1-month drop of -32.77%. Year-to-date, the stock has fallen by -35.90%, and over the past year, it has decreased by -43.37%. <BR><BR>Today, the stock hit a new 52-week low of Rs. 6.15 and has been on a consecutive downward trend for the last two days, resulting in a total decline of -12.59% during this period. Furthermore, JHS Svendgaard Laboratories Ltd is trading below its moving averages across all time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a persistent weakness in price performance.<BR><BR>Investor participation has also decreased, with a delivery volume of 2.96 lacs on March 27, which is down by -0.12% compared to the 5-day average. This decline in trading activity suggests a lack of confidence among investors. <BR><BR>The company's long-term fundamentals are weak, highlighted by a -42.72% compound annual growth rate (CAGR) in operating profits over the last five years and a poor EBIT to interest ratio of -8.30, indicating challenges in servicing its debt. Additionally, the stock has reported negative EBITDA and has consistently underperformed against benchmarks, including a -43.37% return over the past year compared to the BSE500.<BR><BR>In summary, the combination of significant price declines, weak fundamentals, reduced investor participation, and consistent underperformance against market benchmarks are the primary reasons for the falling stock price of JHS Svendgaard Laboratories Ltd.

Which are the latest news on JHS Sven.Lab.?